$11.36
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Daxor Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. The company specializes in blood volume measurement technology focused on blood volume testing innovation. The company markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. The company has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Country

US

CEO

Mr. Michael Feldschuh

IPO date

1983

Employees

0

ISIN

US2394671034

Key stats

Open

$10.11

Volume

760.00

Market cap

$58.38M

Prev. close

$10.11

Impl / hst vl

-

Open interest

$0.00

$10.11

Day’s Range

$11.36

$8.56

52W Range

$14.75

Valuation

33
Valuation score
Overvalued
P/E
6.49
P/S
2,228.37
P/B
1.30
Current ratio
0.08
Debt / Equity
-
ROE
22.50%
Gross margin
-9,372.90%
Income growth
-2,680.34%
FCF growth
-77.75

Analysts estimates

Consensus rating
Buy

The average rating from top 4 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$22.95
The top 3 analysts forecasts that 12-month price may increase by 102.02%, with a low of $22.22 and a high of $24.15
$22.22
Low
$22.95
Avg
$24.15
High
Current price

Earnings

Q4 ‘25 revenue
$8.30K
Q4 ‘25 net income
$9.54M
Revenue
Net income
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply